Phase I/IB Study of Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Washington University School of Medicine
Summary
The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
Eligibility
- Age range
- 18+ years
- Sex
- Female
- Healthy volunteers
- No
Inclusion Criteria: * Diagnosis of recurrent, FIGO grade 3 endometrioid, serous, or mixed high grade uterine or endometrial cancer or uterine carcinosarcoma. Patients must have experienced either prior progression on a platinum-based therapy or intolerance to platinum. Patients with dMMR or MSI-H tumors or targetable HER2 alterations are required to have received prior therapy with appropriate targeted agents. * 1-2 prior lines of anti-cancer therapy are allowed. * Subjects who have received prior treatment with trastuzumab, pembrolizumab, or dostarlimab can enroll in the study. Use of these…
Interventions
- DrugZanzalintinib
Taken by mouth.
- DrugPaclitaxel
175 mg\^m2 intravenous over 3 hours.
Locations (4)
- University of California, San FranciscoSan Francisco, California
- Washington University School of MedicineSt Louis, Missouri
- University of New MexicoAlbuquerque, New Mexico
- University of OklahomaOklahoma City, Oklahoma